4.6 Review

Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 27, Issue 28, Pages -

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i28.4504

Keywords

COVID-19; Angiotensin-converting enzyme 2; Gastrointestinal; Inflammatory bowel disease; Liver; Management

Ask authors/readers for more resources

SARS-CoV-2 may be transmitted via the gastrointestinal tract, leading to digestive symptoms such as anorexia, nausea, vomiting, and diarrhea. Additionally, SARS-CoV-2 has been found in patients' stool, suggesting the possibility of transmission through the fecal-oral route. Liver function should be monitored during COVID-19, especially in more severe cases.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered the causative pathogen of coronavirus disease 2019 (COVID-19) and has become an international danger to human health. Although respiratory transmission and symptoms are still the essential manifestations of COVID-19, the digestive system could be an unconventional or supplementary route for COVID-19 to be transmitted and manifested, most likely due to the presence of angiotensin-converting enzyme 2 (ACE2) in the gastrointestinal tract. In addition, SARS-CoV-2 can trigger hepatic injury via direct binding to the ACE2 receptor in cholangiocytes, antibody-dependent enhancement of infection, systemic inflammatory response syndrome, inflammatory cytokine storms, ischemia/reperfusion injury, and adverse events of treatment drugs. Gastrointestinal symptoms, including anorexia, nausea, vomiting, and diarrhea, which are unusual in patients with COVID-19, and some digestive signs may occur without other respiratory symptoms. Furthermore, SARS-CoV-2 can be found in infected patients' stool, demonstrating the likelihood of transmission through the fecal-oral route. In addition, liver function should be monitored during COVID-19, particularly in more severe cases. This review summarizes the evidence for extra-pulmonary manifestations, mechanisms, and management of COVID-19, particularly those related to the gastrointestinal tract and liver.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available